Corvus Pharmaceuticals, Inc.

As of June 30, 2026, Corvus Pharmaceuticals, Inc. carries a market capitalization of 1.10B, placing it among publicly traded companies globally. Its enterprise value stands at 907.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Corvus Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Corvus Pharmaceuticals, Inc. has 84.12M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Corvus Pharmaceuticals, Inc. maintains a current ratio of 16.16, meaning it holds 16.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Corvus Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -35.43, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -32.93, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 35.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Corvus Pharmaceuticals, Inc.'s stock has gained approximately 52.83% over the past 52 weeks. The 50-day moving average sits at 10.88, while the 200-day moving average is 12.37.

Over the twelve months ended June 30, 2026, Corvus Pharmaceuticals, Inc. generated - - in revenue and converted that into -47.38M in net income, yielding earnings per share of -0.54. EBITDA reached -49.76M, while operating income came in at -49.86M.

As of June 30, 2026, Corvus Pharmaceuticals, Inc. holds 188.39M in cash and equivalents against 637,218.40 in total debt, resulting in a net debt position of -16.55M. Total book value stands at 197.23M, with working capital of 181.44M providing operational flexibility.

Corvus Pharmaceuticals, Inc. produced -38.98M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -610,959.40 in capital expenditures, free cash flow totaled -39.59M - equivalent to -0.45 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.49: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.28, meaning Corvus Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Corvus Pharmaceuticals, Inc. has an Altman Z-Score of 51.51, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.